Floatz logo

Ifosfamide

Mixed Mesodermal (Mullerian) Tumor

GOG FoundationPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Mixed Mesodermal (Mullerian) Tumor cohort.

Asset / SponsorPhaseRating
Carboplatin
Blueprint Medicines Corporation
Phase 3BB
Dkn-01
Leap Therapeutics, Inc.
Phase 2B
Pamiparib
Australia New Zealand Gynaecological Oncology Group
Phase 2CCC
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Carboplatin
Dana-Farber Cancer Institute
Phase 2CCC

View all 12 →

Same molecule, other indications

Ifosfamide is also rated in:

angioimmunoblastic T-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →